Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy

  • Tracy R Daniels-Wells1Email author,
  • Gustavo Helguera1, 9,
  • Richard K Leuchter1,
  • Rafaela Quintero1,
  • Maggie Kozman1,
  • José A Rodríguez1, 2,
  • Elizabeth Ortiz-Sánchez1, 10,
  • Otoniel Martínez-Maza3, 4, 5, 6,
  • Birgit C Schultes7, 8,
  • Christopher F Nicodemus7, 11 and
  • Manuel L Penichet1, 2, 3, 4
BMC Cancer201313:195

DOI: 10.1186/1471-2407-13-195

Received: 5 June 2012

Accepted: 6 March 2013

Published: 17 April 2013

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
5 Jun 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
7 Jun 2012 Author responded Author comments - Tracy Daniels-Wells
Resubmission - Version 3
7 Jun 2012 Submitted Manuscript version 3
10 Sep 2012 Reviewed Reviewer Report - Dev Karan
8 Oct 2012 Reviewed Reviewer Report - Francesco Novelli
12 Oct 2012 Reviewed Reviewer Report - Mirella Giovarelli
14 Oct 2012 Reviewed Reviewer Report - Myron Arlen
17 Dec 2012 Author responded Author comments - Tracy Daniels-Wells
Resubmission - Version 4
17 Dec 2012 Submitted Manuscript version 4
6 Feb 2013 Reviewed Reviewer Report - Francesco Novelli
12 Feb 2013 Reviewed Reviewer Report - Mirella Giovarelli
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
6 Mar 2013 Editorially accepted
17 Apr 2013 Article published 10.1186/1471-2407-13-195

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California
(2)
The Molecular Biology Institute, University of California
(3)
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California
(4)
Jonsson Comprehensive Cancer Center, University of California
(5)
Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California
(6)
Department of Epidemiology, Fielding School of Public Health, University of California
(7)
Advanced Immune Therapeutics, Inc
(8)
Momenta Pharmaceuticals, Inc
(9)
School of Pharmacy and Biochemistry, University of Buenos Aires
(10)
Unit of Biomedical Research in Cancer, Basic Research Division, National Institute of Cancerology
(11)
AIT Strategies

Advertisement